Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib, Obinutuzumab, and Lenalidomide in Untreated MZL
NCT06454968Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in marginal zone lymphoma (MZL), sponsored by Peking Union Medical College Hospital. Primary endpoint: Complete Response Rate at 42 weeks. Started Jun 2024; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT06454968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06454968.